Dirk Scharn

775 total citations
15 papers, 181 citations indexed

About

Dirk Scharn is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Dirk Scharn has authored 15 papers receiving a total of 181 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 6 papers in Hematology and 4 papers in Genetics. Recurrent topics in Dirk Scharn's work include Chemical Synthesis and Analysis (4 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers) and Multiple Myeloma Research and Treatments (3 papers). Dirk Scharn is often cited by papers focused on Chemical Synthesis and Analysis (4 papers), Coagulation, Bradykinin, Polyphosphates, and Angioedema (4 papers) and Multiple Myeloma Research and Treatments (3 papers). Dirk Scharn collaborates with scholars based in Austria, Germany and United Kingdom. Dirk Scharn's co-authors include Karsten Schnatbaum, Uwe Richter, Elsa Locardi, Harald Engelhardt, Thomas Polakowski, Marco H. Hofmann, Anke Baum, Johannes Popow, Ulrike Tontsch-Grunt and Thomas Gerstberger and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Dirk Scharn

14 papers receiving 178 citations

Peers

Countries citing papers authored by Dirk Scharn

Since Specialization

Citations

This map shows the geographic impact of Dirk Scharn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Scharn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Scharn more than expected).

Fields of papers citing papers by Dirk Scharn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Scharn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Scharn. The network helps show where Dirk Scharn may publish in the future.

Co-authorship network of co-authors of Dirk Scharn

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Scharn. A scholar is included among the top collaborators of Dirk Scharn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Scharn. Dirk Scharn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Abstract 1472: Novel EGFR WT sparing, HER2 selective inhibitors for the treatment of HER2 exon 20 insertion driven tumors address a clear unmet medical need 2021 ·Cancer Research ·Ralph A. Neumüller, Birgit Wilding, Dirk Scharn, Dietrich Böse, Valeria Santoro, Daniel Gerlach, Peter Ettmayer, Thomas Gerstberger, Julian E. Fuchs, Matthias Treu, Stephan K. Zahn, Anke Baum, Paolo Chetta, Mark Pearson, Darryl B. McConnell, Norbert Kraut, Flavio Solca	1
2	The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML 2018 ·Oncogene ·Daniel Gerlach, Ulrike Tontsch-Grunt, Anke Baum, Johannes Popow, Dirk Scharn, Marco H. Hofmann, Harald Engelhardt, Onur Kaya, (unknown), Norbert Schweifer, Thomas Gerstberger, Johannes Zuber, Fabio Savarese, Norbert Kraut	66
3	Abstract 2330: BI5: a novel SMAC mimetic that triggers tumor cell death and potentiates PD-1 mediated cancer therapy 2017 ·Cancer Research ·Markus Reschke, (unknown), Ulrich Reiser, Dirk Scharn, Walter Spevak, Alexander Savchenko, Andreas Wernitznig, Martina Sykora, (unknown), (unknown), (unknown), (unknown), Pilar Garin‐Chesa, Jens Quant, Mark Pearson, Darryl B. McConnell, Norbert Kraut, (unknown)	0
4	Abstract 4630: Development of selective and potent CDK8 inhibitors that increase NK cell activity, which translates in tumor surveillance 2017 ·Cancer Research ·Marco H. Hofmann, Harald Engelhardt, Sebastian Carotta, Heribert Arnhof, Dirk Scharn, Marc A. Kerenyi, (unknown), (unknown), (unknown), (unknown), Michael P. Sanderson, (unknown), Renate Schnitzer, Mark Pearson, Darryl B. McConnell, Norbert Kraut, Jürgen Moll	1
5	Effects of the novel BET inhibitor BI 894999 on upregulation of HEXIM1 in cancer cells and on antitumor activity in xenograft tumor models. 2016 ·Journal of Clinical Oncology ·Ulrike Tontsch-Grunt, Fabio Savarese, Anke Baum, Dirk Scharn, Daniel Gerlach, Marco H. Hofmann, Onur Kaya, Norbert Schweifer, Harald Engelhardt, Hanny Musa, (unknown), Gerd Munzert, (unknown)	1
6	Abstract B79: BI 894999, a novel BET inhibitor: Treatment of hematological malignancies by repression of super-enhancer driven oncogenes 2015 ·Molecular Cancer Therapeutics ·Ulrike Tontsch-Grunt, Fabio Savarese, Daniel Gerlach, Davide Gianni, Anke Baum, Dirk Scharn, Harald Engelhardt, Onur Kaya, Norbert Schweifer, Thomas Gerstberger, Norbert Kraut	4
7	Bispyrimidines as Potent Histamine H₄ Receptor Ligands: Delineation of Structure–Activity Relationships and Detailed H₄ Receptor Binding Mode 2013 ·Journal of Medicinal Chemistry ·Harald Engelhardt, Sabine Schultes, Chris de Graaf, Saskia Nijmeijer, Henry F. Vischer, Obbe P. Zuiderveld, (unknown), (unknown), Moriz Mayer, Heribert Arnhof, Dirk Scharn, Eric Haaksma, Iwan J. P. de Esch, Rob Leurs	10
8	Detailed structure–activity relationship of indolecarboxamides as H4 receptor ligands 2012 ·European Journal of Medicinal Chemistry ·Harald Engelhardt, Iwan J. P. de Esch, Daniel Kühn, Rogier A. Smits, Obbe P. Zuiderveld, (unknown), Moriz Mayer, Sebastian Lips, Heribert Arnhof, Dirk Scharn, Eric Haaksma, Rob Leurs	14
9	Novel Small Molecule Bradykinin B ₂ Receptor Antagonists 2009 ·Journal of Medicinal Chemistry ·Christoph Gibson, Karsten Schnatbaum, (unknown), Elsa Locardi, Matthias Paschke, Ulf Reimer, Uwe Richter, Dirk Scharn, Alexander Faußner, Thomas Tradler	21
10	Novel small molecule bradykinin B1 receptor antagonists. Part 2: 5-membered diaminoheterocycles 2009 ·Bioorganic & Medicinal Chemistry Letters ·Gunther Zischinsky, Roland Stragies, (unknown), (unknown), Christoph Gibson, Elsa Locardi, Dirk Scharn, Uwe Richter, (unknown), Klaus Dinkel, Karsten Schnatbaum	5
11	Novel small molecule bradykinin B1 receptor antagonists. Part 1: Benzamides and semicarbazides 2009 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Elsa Locardi, Gunther Zischinsky, Roland Stragies, (unknown), Christoph Gibson, Dirk Scharn, Uwe Richter, (unknown), Klaus Dinkel, Karsten Schnatbaum	5
12	Novel small molecule bradykinin B1 receptor antagonists. Part 3: Hydroxyurea derivatives 2009 ·Bioorganic & Medicinal Chemistry Letters ·Karsten Schnatbaum, (unknown), Roland Stragies, (unknown), Christoph Gibson, Elsa Locardi, Dirk Scharn, Uwe Richter, (unknown), Klaus Dinkel, Gunther Zischinsky	4
13	SAR of N-phenyl piperidine based oral integrin α5β1 antagonists 2009 ·Bioorganic & Medicinal Chemistry Letters ·Gunther Zischinsky, Frank Osterkamp, (unknown), Grit Zahn, Dirk Scharn, (unknown), Roland Stragies	5
14	Discovery of orally available integrin α5β1 antagonists 2009 ·Bioorganic & Medicinal Chemistry Letters ·Gunther Zischinsky, Frank Osterkamp, (unknown), Grit Zahn, Dirk Scharn, (unknown), Roland Stragies	6
15	Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: Increased receptor specificity and in vivo activity 2006 ·Bioorganic & Medicinal Chemistry Letters ·Karsten Schnatbaum, Elsa Locardi, Dirk Scharn, Uwe Richter, Heiko Hawlisch, Jochen Knolle, Thomas Polakowski	38

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact